# Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

> **NCT03515798** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 52 (actual)

## Conditions studied

- Inflammatory Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab Injection
- **DRUG:** neoadjuvant EC-paclitaxel chemotherapy

## Key facts

- **NCT ID:** NCT03515798
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-29
- **Primary completion:** 2022-08-22
- **Final completion:** 2027-08-22
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515798, "Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03515798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*